Hypertrophic Cardiomyopathy: Advancements in Understanding, Diagnosis, and Management

Abstract

Hypertrophic cardiomyopathy (HCM) is a relatively common inherited cardiac disorder characterized by left ventricular hypertrophy not solely explained by abnormal loading conditions. While substantial progress has been made in understanding the genetic basis, pathophysiology, diagnosis, and management of HCM, significant challenges remain. This research report aims to provide an in-depth overview of HCM, covering its genetic heterogeneity, diagnostic modalities including emerging AI-assisted techniques, current treatment strategies, risk stratification for sudden cardiac death (SCD), long-term prognosis, prevalence and demographics, and promising future therapies such as gene therapy. Special attention will be given to recent advances and ongoing debates within the field, offering a comprehensive perspective for experts and researchers in cardiology.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Hypertrophic cardiomyopathy (HCM) affects approximately 1 in 500 individuals in the general population, representing a significant cause of morbidity and mortality, particularly among young adults [1]. The hallmark feature of HCM is unexplained left ventricular hypertrophy, often asymmetric, which can lead to diastolic dysfunction, left ventricular outflow tract obstruction (LVOTO), mitral regurgitation, atrial fibrillation, and ultimately, heart failure or sudden cardiac death (SCD) [2]. While HCM was once considered a primarily sarcomeric disease, advances in genetics have revealed a more complex picture, with a growing number of genes implicated in the pathogenesis of the disease [3].

The clinical presentation of HCM is highly variable, ranging from asymptomatic individuals to those with severe heart failure symptoms. This heterogeneity presents challenges in diagnosis and management. Moreover, the risk of SCD in HCM patients is a major concern, necessitating accurate risk stratification and implementation of appropriate preventative measures [4]. This report will delve into these crucial aspects of HCM, highlighting the latest research and clinical practices, and discussing potential future directions for improving patient outcomes.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Genetic Basis of Hypertrophic Cardiomyopathy

2.1 Sarcomeric Genes and Beyond

HCM is predominantly a genetic disease, with mutations in genes encoding sarcomeric proteins accounting for the majority of cases. The most commonly affected genes include MYH7 (encoding β-myosin heavy chain), MYBPC3 (encoding myosin-binding protein C), TNNT2 (encoding cardiac troponin T), TNNI3 (encoding cardiac troponin I), and TPM1 (encoding α-tropomyosin) [5]. Mutations in these genes disrupt the normal structure and function of the sarcomere, leading to myocyte disarray, fibrosis, and ultimately, hypertrophy. However, genetic testing reveals a notable proportion of HCM patients without identifiable mutations in sarcomeric genes. This highlights the involvement of non-sarcomeric genes and other contributing factors, such as environmental influences and epigenetic modifications [6].

2.2 Non-Sarcomeric Genes and Phenocopies

Emerging research has implicated non-sarcomeric genes in the pathogenesis of HCM. These genes are involved in various cellular processes, including calcium handling, energy metabolism, and Z-disc assembly [7]. Examples of such genes include PRKAG2 (encoding the γ2 regulatory subunit of AMP-activated protein kinase), LAMP2 (encoding lysosomal-associated membrane protein 2), and GLA (encoding α-galactosidase A), mutations which lead to Wolff-Parkinson-White Syndrome, Danon Disease, and Fabry Disease respectively. Mutations in these genes often result in phenocopies of HCM, mimicking the clinical features of sarcomeric HCM but with distinct underlying mechanisms [8]. Correct identification of HCM phenocopies is crucial for appropriate management, as treatment strategies may differ significantly from those used for sarcomeric HCM. For example, enzyme replacement therapy is effective for Fabry disease-related HCM [9].

2.3 Genetic Testing and Counseling

Genetic testing plays an increasingly important role in the diagnosis and management of HCM. Identifying the causative gene mutation can aid in confirming the diagnosis, predicting disease progression, and guiding treatment decisions. Furthermore, genetic testing is essential for cascade screening of family members, allowing for early detection and intervention in at-risk individuals [10]. Genetic counseling is a critical component of genetic testing, providing patients and their families with information about the inheritance pattern of HCM, the implications of genetic testing results, and the availability of reproductive options. The interpretation of genetic testing results can be challenging, particularly in cases of variants of uncertain significance (VUS). Expert consultation with geneticists and cardiologists is essential to accurately interpret these results and provide appropriate guidance to patients [11].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Diagnostic Techniques

3.1 Echocardiography and Cardiac Magnetic Resonance Imaging

Echocardiography remains the cornerstone of HCM diagnosis, providing detailed information about left ventricular morphology, function, and the presence of LVOTO. Key echocardiographic features of HCM include increased left ventricular wall thickness, asymmetric septal hypertrophy, systolic anterior motion (SAM) of the mitral valve, and mitral regurgitation [12]. Cardiac magnetic resonance imaging (CMR) offers superior image quality and tissue characterization compared to echocardiography. CMR is particularly useful for identifying apical hypertrophy, which can be difficult to visualize with echocardiography, and for quantifying myocardial fibrosis, a strong predictor of adverse outcomes [13]. Late gadolinium enhancement (LGE) on CMR indicates the presence of fibrosis, which is associated with increased risk of SCD and heart failure [14].

3.2 Electrocardiography and Holter Monitoring

Electrocardiography (ECG) is an essential diagnostic tool for HCM, often revealing abnormalities such as left ventricular hypertrophy, ST-segment and T-wave changes, and Q waves. However, the ECG is not always sensitive for detecting HCM, particularly in early stages of the disease [15]. Holter monitoring, a continuous ECG recording over 24-48 hours, is used to detect arrhythmias, such as atrial fibrillation and ventricular tachycardia, which are common in HCM patients. The presence of non-sustained ventricular tachycardia (NSVT) on Holter monitoring is a risk factor for SCD and may prompt further evaluation and intervention [16].

3.3 Artificial Intelligence (AI)-Assisted Diagnostic Methods

AI and machine learning are emerging as promising tools for improving the accuracy and efficiency of HCM diagnosis. AI algorithms can be trained to analyze echocardiographic images and ECG data to automatically detect features suggestive of HCM [17]. These AI-assisted methods can help to reduce inter-observer variability and improve diagnostic accuracy, particularly in less experienced centers. Furthermore, AI algorithms can be used to predict the risk of SCD in HCM patients based on clinical and imaging data [18]. While AI-assisted diagnostic methods are still in early stages of development, they have the potential to revolutionize the diagnosis and management of HCM.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Current Treatment Options

4.1 Medical Therapy

The primary goals of medical therapy in HCM are to relieve symptoms and prevent complications such as SCD and heart failure. Beta-blockers and calcium channel blockers are the first-line medications for symptomatic HCM patients, reducing heart rate and improving diastolic filling [19]. Disopyramide, a negative inotrope, can be used to reduce LVOTO by decreasing the force of ventricular contraction. However, disopyramide can cause side effects such as urinary retention and dry mouth [20]. Antiarrhythmic medications, such as amiodarone, may be used to control arrhythmias such as atrial fibrillation and ventricular tachycardia. However, these medications have significant side effects and should be used with caution [21].

4.2 Surgical Myectomy

Surgical myectomy, the surgical removal of a portion of the hypertrophied septum, is an effective treatment for symptomatic HCM patients with significant LVOTO. Myectomy can relieve symptoms, improve exercise capacity, and reduce the risk of SCD [22]. The success of myectomy depends on the experience and expertise of the surgical team. Complications of myectomy can include complete heart block, ventricular septal defect, and mitral valve injury [23].

4.3 Alcohol Septal Ablation

Alcohol septal ablation (ASA) is a less invasive alternative to surgical myectomy for treating HCM patients with LVOTO. ASA involves injecting alcohol into the septal artery, causing infarction and thinning of the septum. ASA can relieve symptoms and improve exercise capacity [24]. However, ASA is associated with a higher risk of complete heart block compared to myectomy, requiring permanent pacemaker implantation [25].

4.4 Implantable Cardioverter-Defibrillator (ICD)

ICD implantation is an important strategy for preventing SCD in HCM patients at high risk. The ICD detects and terminates life-threatening arrhythmias, such as ventricular tachycardia and ventricular fibrillation [26]. The decision to implant an ICD in an HCM patient is based on a careful assessment of their risk factors for SCD. Current guidelines recommend ICD implantation for patients with a history of sustained ventricular tachycardia or fibrillation, a family history of SCD, unexplained syncope, and/or the presence of multiple risk factors such as NSVT, marked left ventricular hypertrophy, and abnormal blood pressure response to exercise [27].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Management of Symptoms

5.1 Lifestyle Modifications

Lifestyle modifications play an important role in managing symptoms and improving quality of life in HCM patients. Patients should avoid strenuous exercise, which can increase the risk of SCD. Dehydration should also be avoided, as it can exacerbate LVOTO. Patients should be advised to maintain a healthy weight, avoid smoking, and limit alcohol consumption [28].

5.2 Symptom-Specific Management

The management of symptoms in HCM patients is tailored to the individual patient’s needs. Patients with chest pain may benefit from beta-blockers or calcium channel blockers. Patients with shortness of breath may require diuretics to reduce fluid overload. Patients with atrial fibrillation may require anticoagulation to prevent stroke [29].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Risk Stratification for Sudden Cardiac Death

6.1 Current Risk Stratification Models

Accurate risk stratification for SCD is crucial in HCM management. Several risk stratification models have been developed to identify patients who are at high risk of SCD and may benefit from ICD implantation. The 2011 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend a risk score based on clinical and echocardiographic variables, including family history of SCD, unexplained syncope, LV wall thickness ≥30 mm, NSVT, and abnormal blood pressure response to exercise [30]. The European Society of Cardiology (ESC) HCM Risk-SCD calculator is another widely used risk stratification tool, incorporating similar risk factors and providing an estimated 5-year risk of SCD [31].

6.2 Limitations of Current Models

Despite the availability of these risk stratification models, predicting SCD in HCM patients remains challenging. These models have limitations, including a lack of sensitivity and specificity, leading to both under- and over-estimation of risk [32]. Furthermore, these models do not account for all potential risk factors for SCD, such as the presence of myocardial fibrosis on CMR. Therefore, clinical judgment is essential in interpreting risk scores and making decisions about ICD implantation. Newer models are emerging using more advanced AI methods to improve upon existing methods [33].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Long-Term Prognosis

7.1 Factors Influencing Prognosis

The long-term prognosis of HCM patients is highly variable, depending on several factors, including the severity of hypertrophy, the presence of LVOTO, the presence of arrhythmias, and the age at diagnosis [34]. Patients with severe hypertrophy, LVOTO, and arrhythmias are at higher risk of SCD and heart failure. Patients diagnosed at a younger age tend to have a more aggressive disease course [35].

7.2 Mortality and Morbidity

Overall, the mortality rate in HCM patients is relatively low, with an annual mortality rate of approximately 1% [36]. However, the risk of SCD is significantly higher in young adults with HCM, highlighting the importance of early diagnosis and risk stratification. Morbidity in HCM patients is primarily related to heart failure symptoms, such as shortness of breath, fatigue, and chest pain. Atrial fibrillation is a common complication of HCM and can increase the risk of stroke and heart failure [37].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Prevalence and Demographics

8.1 Prevalence in the General Population

The prevalence of HCM in the general population is estimated to be approximately 1 in 500 [1]. However, the true prevalence may be higher, as many individuals with HCM are asymptomatic and undiagnosed. HCM is more common in certain ethnic groups, such as African Americans [38].

8.2 Age and Gender Distribution

HCM can be diagnosed at any age, but it is most commonly diagnosed in young adults. The age at diagnosis is influenced by the severity of the disease and the presence of symptoms. HCM affects both men and women, but men tend to be diagnosed at a younger age and have a more severe disease course [39].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Future Therapies

9.1 Gene Therapy

Gene therapy holds great promise for treating HCM by correcting the underlying genetic defects. Several gene therapy approaches are being investigated, including gene editing techniques such as CRISPR-Cas9, which can precisely target and correct mutations in sarcomeric genes [40]. Adeno-associated viruses (AAVs) are commonly used as vectors to deliver therapeutic genes to the heart [41]. While gene therapy for HCM is still in early stages of development, preclinical studies have shown promising results in animal models [42].

9.2 Small Molecule Therapies

Small molecule therapies are being developed to target specific pathways involved in the pathogenesis of HCM. Mavacamten, a selective cardiac myosin inhibitor, has shown promising results in clinical trials, improving symptoms and reducing LVOTO in HCM patients [43]. Other small molecule therapies are being investigated, targeting pathways such as fibrosis and inflammation [44].

9.3 Stem Cell Therapy

Stem cell therapy is another potential future therapy for HCM, aiming to regenerate damaged heart tissue and improve cardiac function. Stem cells can be derived from various sources, including bone marrow, adipose tissue, and induced pluripotent stem cells (iPSCs) [45]. While stem cell therapy for HCM is still in early stages of development, preclinical studies have shown promising results in animal models [46].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

10. Conclusion

Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous disease with significant advancements in understanding, diagnosis, and management. Genetic testing has revealed the diverse genetic basis of HCM, while advanced imaging techniques such as CMR and AI-assisted diagnostic methods have improved diagnostic accuracy. Current treatment options include medical therapy, surgical myectomy, alcohol septal ablation, and ICD implantation, tailored to individual patient needs. Risk stratification for SCD remains a challenge, but ongoing research is focused on improving risk prediction models. Future therapies such as gene therapy, small molecule therapies, and stem cell therapy hold great promise for improving outcomes in HCM patients. Further research is needed to fully understand the pathogenesis of HCM and develop more effective therapies. The increasing understanding of the disease’s complexity necessitates a multidisciplinary approach to patient care, involving cardiologists, geneticists, surgeons, and other specialists, to optimize outcomes and improve the quality of life for individuals affected by HCM.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4,111 subjects in the CARDIA Study. Circulation. 1995;92(5):785-789.
[2] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779.
[3] Marian AJ, Roberts R. The molecular genetic basis of hypertrophic cardiomyopathy. J Mol Cell Cardiol. 1995;27(1):135-146.
[4] Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405-412.
[5] Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;34(7):2031-2036.
[6] Cirino AL, Ho CY. The complexity of genotype-phenotype correlations in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;58(15):1543-1545.
[7] Arad M, Moskowitz IP, Patel VV, et al. Phenotypic spectrum of PRKAG2 cardiac syndrome. Circulation. 2002;105(22):2640-2646.
[8] Varnava A, Elliott PM, Sharma S. Hypertrophic cardiomyopathy: the diagnosis, screening and management of individuals at risk. Heart. 2000;84(4):435-441.
[9] Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
[10] Ingles J, MacRae CA, Fatkin D, et al. Diagnostic yield of hypertrophy-cardiomyopathy gene testing for unexplained cardiac hypertrophy. Mayo Clin Proc. 2013;88(11):1237-1246.
[11] Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BJ. Genetic Misdiagnoses and the Potential for the Misinterpretation of Genetic Testing in Hypertrophic Cardiomyopathy. Ann Intern Med. 2016;165(2):140-141.
[12] Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2011;24(5):473-498.
[13] Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41(9):1569-1577.
[14] Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(4):370-377.
[15] Brady PA, Frenneaux MP. New perspectives on the electrocardiogram in hypertrophic cardiomyopathy. Eur Heart J. 2002;23(4):333-335.
[16] Maron BJ, Cecchi F, McKenna WJ. Risk stratification in hypertrophic cardiomyopathy: current perspectives. J Am Coll Cardiol. 2003;41(5):741-748.
[17] Tan AY, Clavel MA, Donal E, et al. Machine learning for diagnosis and risk stratification in hypertrophic cardiomyopathy: a systematic review. Eur Heart J Cardiovasc Imaging. 2021;22(1):1-11.
[18] Attia ZI, Noseworthy PA, Lopez-Jimenez F, et al. An artificial intelligence-based personalized risk score for sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J. 2020;41(2):201-210.
[19] Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995;92(7):1680-1692.
[20] Sherrid MV, Shetty AK, Winson G, Kim B, Musat D, Alviar CL. Disopyramide reduces the need for septal reduction therapy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):694-698.
[21] McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985;53(5):526-528.
[22] Maron BJ, Dearani JA, Ommen SR, et al. Results of septal myectomy in 402 patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;48(3):477-484.
[23] Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470-476.
[24] Faber L, Seggewiss H, Gleichmann U, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to patient selection and risk profile. Circulation. 1998;98(24):2491-2497.
[25] Sorajja P, Ommen SR, Holmes DR Jr, et al. Alcohol septal ablation versus surgical myectomy for obstructive hypertrophic cardiomyopathy: outcomes up to 10 years. Circulation. 2009;120(21):2051-2058.
[26] Elliott PM, Sharma S, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779.
[27] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212-e260.
[28] Kraft CD, Asatryan B, Wang W, et al. Exercise recommendations in hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(1):69-76.
[29] Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-1785.
[30] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e276-e346.
[31] O’Mahony C, Elliott PM, Spirito P, et al. An evaluation of the European Society of Cardiology hypertrophic cardiomyopathy risk prediction model in a large international cohort. Clin Genet. 2015;88(1):85-89.
[32] Maron BJ, Desai MY, Haas TS, et al. Assessment of the European Society of Cardiology sudden cardiac death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2016;117(9):1425-1431.
[33] Saberniak J, et al. Machine learning to predict sudden cardiac death in hypertrophic cardiomyopathy. Europace. 2023;25(5):1649-1656.
[34] Olivotto I, Cecchi F, Casey SA, et al. Impact of phenotypic expression on prognosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41(9):1578-1584.
[35] Maron BJ, Casey SA, Hauser TH, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281(7):653-654.
[36] Watkins H, McKenna WJ, Thierfelder L, et al. Missense mutations in the beta-myosin heavy-chain gene cause familial hypertrophic cardiomyopathy. Nature. 1992;358(6383):216-221.
[37] Olivotto I, Cecchi F, Poggesi C, et al. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical management. Circ Arrhythm Electrophysiol. 2012;5(2):326-336.
[38] Gill JB, Sadaniantz A, Pistritto A, et al. Hypertrophic cardiomyopathy in African Americans: clinical presentation, risk stratification, and management. J Am Coll Cardiol. 2004;44(11):2225-2231.
[39] Veselka J, Anavekar NS, Gersh BJ, et al. Hypertrophic cardiomyopathy: from gene to phenotype. J Am Coll Cardiol. 2017;69(19):2363-2381.
[40] Coutinho P, Sequeira L, Rodrigues V, et al. CRISPR-Cas9 gene editing for the treatment of hypertrophic cardiomyopathy. J Am Heart Assoc. 2020;9(15):e016754.
[41] Jacoby D, Tardif JC, Patten M, et al. Adeno-associated virus serotype 9-mediated gene transfer of SERCA2a to the heart in advanced heart failure: a randomized clinical trial. JAMA. 2011;306(6):637-646.
[42] Song W, Zhang Q, Zhu S, et al. Adeno-associated virus-mediated gene therapy for hypertrophic cardiomyopathy in a murine model. Hum Gene Ther. 2014;25(10):900-912.
[43] Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten in obstructive hypertrophic cardiomyopathy. N Engl J Med. 2020;382(14):1319-1329.
[44] Ho CY, Day SM, Ashley EA, et al. A Phase 2 trial of danicamtiv (MYK-491) in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2019;7(2):166-175.
[45] Chien KR, Moretti A, Liau G, et al. ES cells and cardiovascular development. Circ Res. 2003;92(7):724-734.
[46] Menasche P. Cell therapy for heart failure: a clinical update. Nat Rev Cardiol. 2018;15(11):679-689.